Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
25,007
Total Claims
$9.8M
Drug Cost
709
Beneficiaries
$14K
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+253%
Cost per patient vs peers
$14K vs $3,933 avg
+18%
Brand preference vs peers
60.4% vs 51.2% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
Brand vs Generic
Brand: 13,393 claims · $9.4M
Generic: 8,790 claims · $361K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 2,055 | $807K |
| Lipase/Protease/Amylase | 357 | $757K |
| Dulaglutide | 678 | $727K |
| Denosumab | 409 | $706K |
| Dapagliflozin Propanediol | 1,005 | $653K |
| Empagliflozin | 667 | $469K |
| Linagliptin | 764 | $466K |
| Finerenone | 545 | $405K |
| Semaglutide | 390 | $405K |
| Semaglutide | 299 | $332K |
| Lipase/Protease/Amylase | 151 | $314K |
| Sitagliptin Phos/Metformin Hcl | 507 | $305K |
| Tirzepatide | 241 | $299K |
| Evolocumab | 241 | $264K |
| Linaclotide | 302 | $241K |
Prescribing Profile
Patient Profile
76
Avg Age
67%
Female
2.08
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About